一项记录并进一步描述 Palovarotene 对进行性骨化性纤维发育不良 (FOP) 患者长期安全性和有效性的研究 (FOPal)
一项国际观察性登记研究,进一步描述 Palovarotene 对进行性骨化性纤维发育不良 (FOP) 患者的长期安全性和有效性
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).
FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).
HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).
This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.
The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.
This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.
In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.
研究概览
地位
条件
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Ipsen Clinical Study Enquiries
- 电话号码:see email
- 邮箱:clinical.trials@ipsen.com
学习地点
-
-
-
Edmonton、加拿大
- 招聘中
- Edmonton Clinic Health Academy (ECHA)- University of Alberta
-
Oakville、加拿大
- 主动,不招人
- Bone Research and Education Centre
-
Toronto、加拿大
- 招聘中
- University Health Network (UHN) - Toronto General
-
-
-
-
California
-
San Francisco、California、美国、94103
- 招聘中
- The Regents of the University of California
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adults and children with FOP who have been prescribed palovarotene, as per local label, by their treating physician for which informed consent has been obtained and maintained. Participants cannot be included if they are currently participating in a palovarotene clinical trial or an interventional clinical trial for FOP or if they have any contraindication for palovarotene (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
描述
Inclusion Criteria :
- Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
- Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.
Exclusion Criteria :
- Currently participating in a palovarotene clinical trial;
- Currently participating in any interventional clinical trial for FOP;
- Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
学习计划
研究是如何设计的?
设计细节
- 观测模型:OTHER
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Exposed Cohort
Participants treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) |
|
Unexposed Cohort
Participants untreated with palovarotene |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene
大体时间:From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC). |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With Serious and Non-serious treatment-related TEAEs
大体时间:From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene
大体时间:From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
|
Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.
大体时间:From Baseline up to 30 days after the last palovarotene dose.
|
Adverse events will be coded according to MedDRA and will be classified by PT and SOC. |
From Baseline up to 30 days after the last palovarotene dose.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
爆发次数
大体时间:从纳入基线之前的 12 个月到 11 年。
|
从纳入基线之前的 12 个月到 11 年。
|
|
|
每个参与者影响的位置数量
大体时间:从基线到每年至11年。
|
从基线到每年至11年。
|
|
|
每个位置的影响位置的演变(位置受影响多少次)
大体时间:从基线开始,每年一次,直至十一年。
|
从基线开始,每年一次,直至十一年。
|
|
|
FOP暴露并暴露于palovarotene的参与者进行慢性治疗的参与者的平均剂量/年份
大体时间:从基线开始,每六个月一次,直至十一年一次。
|
从基线开始,每六个月一次,直至十一年一次。
|
|
|
FOP暴露并暴露于palovarotene进行爆发治疗的参与者的核苷酸的平均剂量/周期
大体时间:从基线开始,每六个月一次,直至十一年一次。
|
从基线开始,每六个月一次,直至十一年一次。
|
|
|
Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score
大体时间:From Baseline and every six months up to eleven years.
|
The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in use of assistive devices
大体时间:From Baseline and every six months up to eleven years.
|
Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score
大体时间:From Baseline and every six months up to eleven years.
|
Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)
大体时间:From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)
大体时间:From Baseline and every six months up to eleven years.
|
The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in absolute and percent predicted FEV1/FVC ratio
大体时间:From Baseline and every six months up to eleven years.
|
The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)
大体时间:From Baseline and every six months up to eleven years.
|
The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants ≥15 years old
大体时间:From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows:
|
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old
大体时间:From Baseline and every six months up to eleven years.
|
PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health). If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall
大体时间:From Baseline and every six months up to eleven years.
|
The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit. |
From Baseline and every six months up to eleven years.
|
|
Number of flare-up outcomes
大体时间:From Baseline and every six months up to eleven years.
|
Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported. |
From Baseline and every six months up to eleven years.
|
|
Flare-up Duration
大体时间:From Baseline and every six months up to eleven years.
|
Flare-up duration will be assessed by body location and overall, at each visit. |
From Baseline and every six months up to eleven years.
|
|
Movement mobility change
大体时间:From Baseline and annually up to eleven years.
|
Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement) |
From Baseline and annually up to eleven years.
|
|
Movement mobility outcomes: Percentage of participants with new bone growth overall and by flare-up status
大体时间:From Baseline and every six months up to eleven years.
|
The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected. |
From Baseline and every six months up to eleven years.
|
|
Percentage of participants with any fractures overall
大体时间:From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Change from Baseline in annualized number of fractures by body location and overall
大体时间:From baseline up to 30 days after the last palovarotene dose.
|
Assessed by radiological imaging and clinical examination. |
From baseline up to 30 days after the last palovarotene dose.
|
|
Incidence of pregnancy
大体时间:From Baseline and every month up to 30 days after the last palovarotene dose.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy and the health status of the baby will be verified |
From Baseline and every month up to 30 days after the last palovarotene dose.
|
|
Description of pregnancy characteristics and outcomes
大体时间:From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of pregnancy related Adverse Events (AEs)
大体时间:From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
大体时间:From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy. |
From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.
|
|
Description of birth and developmental outcomes through the first year after birth
大体时间:From Baseline and every six months up to eleven years.
|
Linear height and knee height velocity will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Change from Baseline in height z-score
大体时间:From Baseline and every six months up to eleven years.
|
Linear height z-score will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Mean difference between chronological age and bone age
大体时间:From Baseline and every six months up to eleven years.
|
Bone age (assessment as per the SmPC/PI) and chronological age will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From Baseline and every six months up to eleven years.
|
|
Frequency of premature physeal closure (PPC) overall
大体时间:From baseline up to 30 days after the last palovarotene dose
|
Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached. |
From baseline up to 30 days after the last palovarotene dose
|
合作者和调查者
赞助
调查人员
- 研究主任:Ipsen Medical, Director、Ipsen
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 共享时间框架
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 共享访问标准
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.